Cost-effectiveness analysis of COVID-19 variants effects in an age-structured model.

Cost-effectiveness analysis of COVID-19 variants effects in an age-structured model.

Publication date: Sep 22, 2023

This study analyzes the impact of COVID-19 variants on cost-effectiveness across age groups, considering vaccination efforts and nonpharmaceutical interventions in Republic of Korea. We aim to assess the costs needed to reduce COVID-19 cases and deaths using age-structured model. The proposed age-structured model analyzes COVID-19 transmission dynamics, evaluates vaccination effectiveness, and assesses the impact of the Delta and Omicron variants. The model is fitted using data from the Republic of Korea between February 2021 and November 2022. The cost-effectiveness of interventions, medical costs, and the cost of death for different age groups are evaluated through analysis. The impact of different variants on cases and deaths is also analyzed, with the Omicron variant increasing transmission rates and decreasing case-fatality rates compared to the Delta variant. The cost of interventions and deaths is higher for older age groups during both outbreaks, with the Omicron outbreak resulting in a higher overall cost due to increased medical costs and interventions. This analysis shows that the daily cost per person for both the Delta and Omicron variants falls within a similar range of approximately $10-$35. This highlights the importance of conducting cost-effect analyses when evaluating the impact of COVID-19 variants.

Open Access PDF

Concepts Keywords
Daily Age
Fatality Analyzes
Korea Cost
November Costs
Vaccination Covid


Type Source Name
disease VO effectiveness
disease MESH COVID-19
disease VO vaccination
disease MESH death
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease IDO country
disease MESH infections
disease VO effective
disease VO PreM
disease VO time
pathway REACTOME Reproduction
disease VO age
disease VO vaccine
disease IDO intervention
disease VO vaccine effectiveness
disease VO vaccine efficacy
disease VO Canada
disease VO vaccinated
disease VO dose
disease VO population
disease VO vaccination coverage
disease VO dead
disease IDO infection
disease IDO susceptibility
disease IDO infectivity
disease VO unvaccinated
disease IDO susceptible population
disease VO USA
disease VO organization
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Iodine
disease MESH vector borne diseases
disease MESH yellow fever
disease MESH premature mortalities
drug DRUGBANK Trestolone

Original Article

(Visited 1 times, 1 visits today)